QNRX

Business Context and Reporting Period

Company: Quoin Pharmaceuticals, Ltd. (QNRX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Quoin is a late-stage clinical specialty pharmaceutical company focused on rare and orphan diseases. Its lead product, QRX003, is a topical lotion in pivotal registrational clinical testing for Netherton Syndrome (NS). The company has no commercialized products and has generated no revenue to date. It operates as a "smaller reporting company" and is incorporated in Israel with principal executive offices in Ashburn, Virginia.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased by approximately $6.8 million (76%) year-over-year, driven primarily by a $6.2 million increase in R&D expenses.
• R&D Acceleration: R&D expenses rose 172% to $9.8 million, attributed to increased expenditures on clinical studies for QRX003, manufacturing costs for clinical materials, and higher internal compensation allocations.
• Capital Raise: The company completed an October 2025 Private Placement, raising approximately $15 million in net proceeds. This included the issuance of ordinary shares, pre-funded warrants, and four series of ordinary warrants (Series H, I, J, and K).
• ADS Reverse Split: Effective April 9, 2025, the company executed a 1-for-35 reverse split of its American Depositary Shares (ADSs) to regain compliance with Nasdaq listing requirements. All historical share data has been retroactively adjusted.
• Warrant Exercises: During 2025, the company received approximately $3.5 million from the exercise of warrants issued in the December 2024 offering.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Clinical Progress: QRX003 is in late-stage clinical development for Netherton Syndrome. In March 2026, the FDA indicated that a single Phase 3 study may be sufficient for approval and expressed openness to an alternative study design without a traditional upfront vehicle control. The company is also advancing QRX003 for Peeling Skin Syndrome and developing QRX009 (topical rapamycin formulations).
• Commercial Strategy: Quoin plans to self-commercialize in the U.S., Western Europe, and Japan, while leveraging nine existing commercial partnerships covering 61 other countries.
• Capital Needs: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least one year from the issuance of the financial statements. Additional capital is required to fund operations and complete clinical development.

Risks and Contingencies

• Going Concern: The company has an accumulated deficit of $71.0 million and relies on future financing, which may not be available on acceptable terms or at all.
• Financing Restrictions: The October 2025 Private Placement agreement includes restrictive covenants prohibiting variable rate financings until April 2026 and equity financings below a specific price until June 2026, potentially limiting future fundraising flexibility.
• Regulatory Uncertainty: Success depends on obtaining FDA and other regulatory approvals, which are not guaranteed. Clinical trial results may not be successful, or trials may be delayed.
• Third-Party Reliance: The company relies on third parties for manufacturing, clinical trial conduct, and supply of active pharmaceutical ingredients.

Key Facts for Investor Verification

• Liquidity Runway: Verify the sufficiency of the $18.7 million in cash and investments against the projected burn rate, given the "substantial doubt" going concern warning.
• Financing Covenants: Review the specific restrictions in the October 2025 Purchase Agreement regarding future equity issuances and variable rate financing.
• Clinical Trial Status: Monitor the recruitment and data readouts for the pivotal Phase 3 studies of QRX003 for Netherton Syndrome, particularly the FDA's acceptance of the alternative study design.
• Warrant Expiration and Terms: Assess the dilution potential and exercise terms of the outstanding Series H, I, J, and K warrants, which have varying expiration dates tied to clinical milestones or fixed dates.
• Related Party Transactions: Note the significant indebtedness to officers (Dr. Myers and Ms. Carter) totaling approximately $2.3 million as of December 31, 2025.